Your session is about to expire
← Back to Search
Semaglutide + Closed-Loop Therapy for Type 1 Diabetes (SEMA-AP Trial)
SEMA-AP Trial Summary
This trial is testing if semaglutide, a once-weekly injectable medication, can improve glucose control in those with type 1 diabetes when used with a closed-loop insulin system.
SEMA-AP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SEMA-AP Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with Type 1 Diabetes for at least a year.You are currently breastfeeding.I have used a GLP1-receptor agonist in the last 2 weeks.I or my family have a history of medullary thyroid cancer or MEN2.I do not have severe eye or stomach issues related to diabetes.I have used diabetes medication other than insulin for less than 2 weeks.I had a severe low blood sugar episode that caused a seizure, unconsciousness, or an ER visit in the last 3 months.My kidney function is severely impaired, with an eGFR below 15.I agree to use effective birth control and avoid pregnancy during the trial.I have had pancreatitis or gallbladder disease before.You have had a bad reaction to GLP1-RAs before.I had weight loss surgery less than 6 months ago.I regularly take hydroxyurea and plan to use a Dexcom G6.Your body mass index is less than 21.I have been using an insulin pump for at least 3 months.I have had severe diabetic ketoacidosis requiring IV insulin in the last 6 months.Your glycated hemoglobin (HbA1c) level is up to 11% in a blood test taken within the last 6 months before joining the study.
- Group 1: Placebo + closed-loop insulin system
- Group 2: Semaglutide, Ozempic® (at maximum tolerated dose) + closed-loop insulin system
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are enrolled in this research project?
"Yes, this is an ongoing recruitment effort as indicated by the clinicaltrials.gov listing. This particular trial was posted on 8/2/2022 and updated as recently as 10/3/2022. They are looking for 28 participants at a single site."
Can patients still join this particular research project?
"That is correct, the information available on clinicaltrials.gov reveals that this trial is still recruiting patients. This study was initially posted on August 2nd, 2020 and has been edited as recently as October 3rd, 2020. The researchers conducting this trial are looking for 28 individuals at a single location."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Research Institute of the McGill University Health Centre: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger